A Phase 1/2 interventional study of ALXN1210 in PNH, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-16.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca — 3 open to participants now, 7 under way, 2 of them phase 3. Hemoglobinuria, Paroxysmal · AstraZeneca.
Among the 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca, this one is the 16th largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2015, is the only one in phase 1/2, and was the 12th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →3 of the 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca are open now, in 8 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
Alexion Pharmaceuticals, Inc. · Sites in Canada, France, United Kingdom
Ages 12–17
Alexion Pharmaceuticals, Inc. · Sites in United States, Australia, France and 4 more countries
Women only
By country, each count listing its studies:
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 12 · Phase 4 2
First in 2004; this study’s year is marked. 1 started in 2015.
This study's enrollment of 13 is below the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 26 across the 23 interventional studies, 75 across the 10 observational. Of the 26 that completed or were terminated, 18 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
1 of the studies in Hemoglobinuria, Paroxysmal by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06449001Phase 3Alexion Pharmaceuticals, Inc.Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis | 2027-05-28 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluated the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of multiple intravenous (IV) doses of ALXN1210 administered to participants with PNH who have not previously been treated with complement inhibitor.
The data presented is up to the Primary Completion date of the study and is for the 24-week Primary Evaluation period. The study also includes an Extension Period of up to 5 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were administered ALXN1210 900 mg. In the Extension period participants continued at the same dose and frequency as the Primary Evaluation Period.
Biological: ALXN1210
Participants were administered ALXN1210 1800 mg. In the Extension period participants continued at the same dose and frequency as the Primary Evaluation Period.
Biological: ALXN1210
Participants were administered ravulizumab as an IV infusion every 4 weeks.
Percent Change In Lactate Dehydrogenase (LDH) Levels From Baseline To Day 169
Baseline was defined as the average of all available assessments prior to first ALXN1210 infusion.
Time frame: Baseline, Day 169
Percent Change In Free Hemoglobin Levels From Baseline To Day 169 And Day 1821
Baseline was defined as the last non-missing assessment value prior to the first ALXN1210 infusion.
Time frame: Baseline, Day 169, Day 1821
Percent Change In Haptoglobin Levels From Baseline To Day 169 And Day 1821
Baseline was defined as the last non-missing assessment value prior to the first ALXN1210 infusion.
Time frame: Baseline, Day 169, Day 1821
Percent Change In Reticulocyte/Erythrocyte Count From Baseline To Day 169 And Day 1821
Baseline was defined as the last non-missing assessment value prior to the first ALXN1210 infusion.
Time frame: Baseline, Day 169, Day 1821
Percent Change In Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell (RBC) Clones From Baseline To Day 169 And Day 1933
Baseline was defined as the last non-missing assessment value prior to the first ALXN1210 infusion.
Time frame: Baseline, Day 169, Day 1933
Percent Change In D-dimer Levels From Baseline To Day 169 And Day 1821
Baseline was defined as the last non-missing assessment value prior to the first ALXN1210 infusion.
Time frame: Baseline, Day 169, Day 1821
Change In Clinical Manifestations Of PNH From Baseline To Day 169 And Day 1821
Clinical manifestations are defined as fatigue, abdominal pain, dyspnea, dysphagia, chest pain, and erectile dysfunction (ED) by cohort. Improvement is defined as present at baseline and absent at Day 169 endpoint. Worsening is defined as absent at Baseline and present at Day 169 endpoint.
Time frame: Baseline, Day 169, Day 1821
Area Under The Serum Concentration-versus-time-curve From Time 0 (Dosing) To The Last Quantifiable Concentration (AUCt) At Day 1
AUCt reported in hours\*microgram/milliliter (h\*ug/mL).
Time frame: Day 1
AUCt/ Dose-normalized (D) At Day 1
Time frame: Day 1
Area Under The Serum Concentration-versus-time-curve From Time 0 (Dosing) To The End Of The Dosing Interval (AUCtau) At Day 141
Time frame: Day 141
AUCtau/D At Day 141
Time frame: Day 141
Maximum Observed Serum Concentration (Cmax) At Day 1 And Day 141
Time frame: Day 1 and Day 141
Cmax/D At Day 1 And Day 141
Time frame: Day 1 and Day 141
Concentration At The End Of The Dosage Interval (Ctrough) At Day 1 And At Day 141
Time frame: Day 1 and Day 141
Time To Maximum Observed Serum Concentration (Tmax) At Day 1 And Day 141
Time frame: Day 1 and Day 141
Percent Change In Chicken Red Blood Cell (cRBC) Hemolysis From Baseline To Day 1709
Time frame: Baseline, Day 1709
Percent Change In Free Complement Component 5 (C5) Concentration From Baseline To Day 1709
Time frame: Baseline, Day 1709
Percent Change In Total C5 Concentration From Baseline To Day 1709
Time frame: Baseline, Day 1709
Participants Experiencing Antidrug Antibodies (ADAs)
Time frame: Day 1821
| Milestone | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 |
|---|---|---|
| Started | 6 | 7 |
| Completed | 6 | 7 |
| Not completed | 0 | 0 |
| Milestone | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 |
|---|---|---|
| Started | 6 | 7 |
| Completed | 5 | 7 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Baseline was defined as the average of all available assessments prior to first ALXN1210 infusion.
| percent change | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 |
|---|---|---|
| Percent Change In Lactate Dehydrogenase (LDH) Levels From Baseline To Day 169 | -85.952 ± 3.1897 | -84.736 ± 3.7736 |
Baseline was defined as the last non-missing assessment value prior to the first ALXN1210 infusion.
| percent change | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 |
|---|---|---|
| Day 169 | -22.335 ± 42.2249 | -43.969 ± 24.7674 |
| Day 1821 | -35.062 ± 30.9356 | 24.435 ± 178.7882 |
Baseline was defined as the last non-missing assessment value prior to the first ALXN1210 infusion.
| percent change | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 |
|---|---|---|
| Day 169 | 40.0000 ± 55.13620 | 17.1429 ± 45.35574 |
| Day 1821 | 72.0000 ± 144.81022 | 62.5000 ± 125.00000 |
Baseline was defined as the last non-missing assessment value prior to the first ALXN1210 infusion.
| percent change | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 |
|---|---|---|
| Day 169 | -21.203 ± 14.1461 | 28.784 ± 54.2636 |
| Day 1821 | -32.736 ± 18.8997 | 9.763 ± 22.5892 |
Baseline was defined as the last non-missing assessment value prior to the first ALXN1210 infusion.
| percent change | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 |
|---|---|---|
| Day 169 | 7.873 ± 19.3064 | 25.840 ± 62.9677 |
| Day 1933 | 15.927 ± 34.8796 | 13.960 ± 78.9414 |
Baseline was defined as the last non-missing assessment value prior to the first ALXN1210 infusion.
| percent change | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 |
|---|---|---|
| Day 169 | -27.42 ± 40.015 | -0.49 ± 73.116 |
| Day 1821 | -12.74 ± 54.821 | 25.15 ± 43.861 |
Clinical manifestations are defined as fatigue, abdominal pain, dyspnea, dysphagia, chest pain, and erectile dysfunction (ED) by cohort. Improvement is defined as present at baseline and absent at Day 169 endpoint. Worsening is defined as absent at Baseline and present at Day 169 endpoint.
| Participants | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 |
|---|---|---|
| Fatigue: Day 169 — Improved from Baseline | 1 | 1 |
| Fatigue: Day 169 — Worsened from Baseline | 0 | 0 |
| Fatigue: Day 169 — No Change/Not Applicable | 5 | 6 |
| Fatigue: Day 1821 — Improved from Baseline | 2 | 1 |
| Fatigue: Day 1821 — Worsened from Baseline | 0 | 0 |
| Fatigue: Day 1821 — No Change/Not Applicable | 3 | 3 |
| Abdominal pain: Day 169 — Improved from Baseline | 0 | 3 |
| Abdominal pain: Day 169 — Worsened from Baseline | 0 | 0 |
| Abdominal pain: Day 169 — No Change/Not Applicable | 6 | 4 |
| Abdominal pain: Day 1821 — Improved from Baseline | 0 | 2 |
| Abdominal pain: Day 1821 — Worsened from Baseline | 0 | 0 |
| Abdominal pain: Day 1821 — No Change/Not Applicable | 5 | 2 |
| Dyspnoea: Day 169 — Improved from Baseline | 2 | 1 |
| Dyspnoea: Day 169 — Worsened from Baseline | 0 | 0 |
| Dyspnoea: Day 169 — No Change/Not Applicable | 4 | 6 |
| Dyspnoea: Day 1821 — Improved from Baseline | 2 | 1 |
| Dyspnoea: Day 1821 — Worsened from Baseline | 0 | 0 |
| Dyspnoea: Day 1821 — No Change/Not Applicable | 3 | 3 |
| Dysphagia: Day 169 — Improved from Baseline | 0 | 1 |
| Dysphagia: Day 169 — Worsened from Baseline | 0 | 0 |
| Dysphagia: Day 169 — No Change/Not Applicable | 6 | 6 |
| Dysphagia: Day 1821 — Improved from Baseline | 0 | 0 |
| Dysphagia: Day 1821 — Worsened from Baseline | 0 | 0 |
| Dysphagia: Day 1821 — No Change/Not Applicable | 5 | 4 |
| Chest pain: Day 169 — Improved from Baseline | 0 | 2 |
| Chest pain: Day 169 — Worsened from Baseline | 0 | 0 |
| Chest pain: Day 169 — No Change/Not Applicable | 6 | 5 |
| Chest pain: Day 1821 — Improved from Baseline | 0 | 1 |
| Chest pain: Day 1821 — Worsened from Baseline | 0 | 0 |
| Chest pain: Day 1821 — No Change/Not Applicable | 5 | 3 |
| ED: Day 169 — Improved from Baseline | 1 | 0 |
| ED: Day 169 — Worsened from Baseline | 0 | 0 |
| ED: Day 169 — No Change/Not Applicable | 5 | 7 |
| ED: Day 1821 — Improved from Baseline | 1 | 0 |
| ED: Day 1821 — Worsened from Baseline | 0 | 0 |
| ED: Day 1821 — No Change/Not Applicable | 3 | 1 |
AUCt reported in hours\*microgram/milliliter (h\*ug/mL).
| h*ug/mL | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 |
|---|---|---|
| Area Under The Serum Concentration-versus-time-curve From Time 0 (Dosing) To The Last Quantifiable Concentration (AUCt) At Day 1 | 14273.95 ± 4907.438 | 42366.62 ± 3710.120 |
| h*ug/mL/mg | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 |
|---|---|---|
| AUCt/ Dose-normalized (D) At Day 1 | 35.68 ± 12.269 | 70.61 ± 6.184 |
| h*ug/mL | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 |
|---|---|---|
| Area Under The Serum Concentration-versus-time-curve From Time 0 (Dosing) To The End Of The Dosing Interval (AUCtau) At Day 141 | 216515.22 ± 68099.982 | 217936.47 ± 31023.979 |
| h*ug/mL/mg | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 |
|---|---|---|
| AUCtau/D At Day 141 | 240.57 ± 75.667 | 242.15 ± 34.471 |
| ug/mL | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 |
|---|---|---|
| Day 1 | 114.00 ± 15.556 | 203.50 ± 10.279 |
| Day 141 | 514.00 ± 147.078 | 512.25 ± 64.958 |
| ug/mL/mg | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 |
|---|---|---|
| Day 1 | 0.29 ± 0.039 | 0.34 ± 0.017 |
| Day 141 | 0.57 ± 0.163 | 0.57 ± 0.072 |
| ug/mL | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 |
|---|---|---|
| Day 1 | 73.25 ± 18.173 | 80.50 ± 6.541 |
| Day 141 | 243.50 ± 126.572 | 204.00 ± 56.586 |
| h | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 |
|---|---|---|
| Day 1 | 2.38 ± 2.404 | 1.88 ± 0.957 |
| Day 141 | 4.03 ± 0.035 | 2.40 ± 1.124 |
| percent change | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 |
|---|---|---|
| Percent Change In Chicken Red Blood Cell (cRBC) Hemolysis From Baseline To Day 1709 | -72.316 ± 19.0919 | -97.314 ± 3.2298 |
| percent change | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 |
|---|---|---|
| Percent Change In Free Complement Component 5 (C5) Concentration From Baseline To Day 1709 | -99.839 ± 0.0130 | -99.802 ± 0.0950 |
| percent change | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 |
|---|---|---|
| Percent Change In Total C5 Concentration From Baseline To Day 1709 | 65.852 ± 31.2054 | 86.676 ± 24.6721 |
| Participants | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 |
|---|---|---|
| Participants Experiencing Antidrug Antibodies (ADAs) | 0 | 0 |
Baseline was defined as the average of all available assessments prior to first ALXN1210 infusion.
| percent change | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 |
|---|---|---|
| Percent Change In LDH Levels From Baseline To Day 1821 | -86.244 ± 4.7348 | -84.413 ± 3.6473 |
Collected over Day 1 through Day 1957. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ALXN1210 Cohort 1 | 0/6 (0%) | 3/6 (50%) | 6/6 (100%) |
| ALXN1210 Cohort 2 | 0/7 (0%) | 4/7 (57.1%) | 7/7 (100%) |
| Event | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/6 | 2/7 |
| Tubo-ovarian abscessInfections and infestations | 1/6 | 0/7 |
| Bile duct stoneHepatobiliary disorders | 1/6 | 0/7 |
| CholangitisHepatobiliary disorders | 1/6 | 0/7 |
| Cholangitis acuteHepatobiliary disorders | 1/6 | 0/7 |
| ContusionInjury, poisoning and procedural complications | 1/6 | 0/7 |
| Meningococcal infectionInfections and infestations | 0/6 | 1/7 |
| Parvovirus infectionInfections and infestations | 0/6 | 1/7 |
| PneumoniaInfections and infestations | 0/6 | 1/7 |
| Cholecystitis acuteHepatobiliary disorders | 0/6 | 1/7 |
| Event | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 3/6 | 6/7 |
| HeadacheNervous system disorders | 2/6 | 4/7 |
| Abdominal painGastrointestinal disorders | 3/6 | 2/7 |
| PyrexiaGeneral disorders | 3/6 | 0/7 |
| ConstipationGastrointestinal disorders | 1/6 | 3/7 |
| DizzinessNervous system disorders | 2/6 | 0/7 |
| FatigueGeneral disorders | 2/6 | 2/7 |
| Back painMusculoskeletal and connective tissue disorders | 2/6 | 2/7 |
| DiarrhoeaGastrointestinal disorders | 2/6 | 2/7 |
| HordeolumInfections and infestations | 0/6 | 2/7 |
| Age, Continuous(years) | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 | Total |
|---|---|---|---|
| Mean | 41.1 ± 10.87 | 43.6 ± 13.48 | 42.4 ± 11.91 |
| Sex: Female, Male(Participants) | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 | Total |
|---|---|---|---|
| Female | 2 | 5 | 7 |
| Male | 4 | 2 | 6 |
| Race/Ethnicity, Customized(participants) | ALXN1210 Cohort 1 | ALXN1210 Cohort 2 | Total |
|---|---|---|---|
| Asian | 6 | 6 | 12 |
| White | 0 | 1 | 1 |
Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
Supporting information: Study protocol, Clinical study report
Ran from Nov 2015 to primary completion in Jul 2016, 8 months.
Results were first posted in Jan 2018, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ravulizumab
Alexion Pharmaceuticals, Inc. →